- Conditions
- Cancer
- Interventions
- therapeutic autologous lymphocytes
- Biological
- Lead sponsor
- Roger Williams Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 939
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
- Interventions
- CT-0508, Pembrolizumab
- Biological
- Lead sponsor
- Carisma Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 7
- States / cities
- Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
- Conditions
- Hematuria - Cause Not Known
- Interventions
- Cxbladder Triage Plus
- Diagnostic Test
- Lead sponsor
- Pacific Edge Limited
- Industry
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Homewood, Alabama • Mobile, Alabama • Fresno, California + 15 more
- Conditions
- Bladder Cancer
- Interventions
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
- Drug · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 907 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
- Conditions
- Bladder Cancer
- Interventions
- Docetaxel, Gemcitabine
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Lymphoma, Sarcoma, Bladder Cancer, Melanoma, IDH1 Mutated Solid Tumors, IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
- Interventions
- Toca 511, Toca FC
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Miami, Florida • Houston, Texas
- Conditions
- Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
- Interventions
- Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
- Interventions
- MLN8054
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
- Interventions
- bupropion hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Bladder Cancer
- Interventions
- Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 342 more
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
- Interventions
- EN3348, Mitomycin C
- Biological
- Lead sponsor
- Bioniche Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 56
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
- Conditions
- Bladder Cancer, High Risk Superficial
- Interventions
- Bacillus Calmette-Guérin (BCG)
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
- Conditions
- Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
- Interventions
- CARES Intervention
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more
- Conditions
- Prostate Cancer, Bladder Cancer, Erectile Dysfunction, Incontinence
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 87,820 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1988 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer
- Interventions
- Defined Green Tea Catechin Extract, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Therapeutic Conventional Surgery
- Dietary Supplement · Other · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more
- Conditions
- Advanced Malignant Solid Tumor, Solid Tumor Cancer
- Interventions
- PLT012
- Drug
- Lead sponsor
- Pilatus Biosciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Dallas, Texas • Houston, Texas
- Conditions
- Bladder Cancer, Urinary Cancer, Nonmuscle Invasive Bladder Cancer
- Interventions
- specimen samples, questionnaires
- Genetic · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer, Bladder Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 5,950 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
- Interventions
- BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Interventions
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Diagnostic Test · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
- Interventions
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Solid Tumors, HER2 Mutation
- Interventions
- BAY2927088
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more